Comparative Pharmacology
Head-to-head clinical analysis: BROMDAY versus ILEVRO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BROMDAY versus ILEVRO.
BROMDAY vs ILEVRO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Brompheniramine is a first-generation alkylamine antihistamine that competitively antagonizes histamine at H1 receptor sites, thereby suppressing histamine-mediated allergic and vasodilatory responses.
Nepafenac is a prodrug that is metabolized to amfenac, a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX) activity, reducing prostaglandin synthesis.
1-2 drops in each affected eye every 4-6 hours as needed, not to exceed 4 doses per day.
1 drop of the 0.3% ophthalmic solution administered to the affected eye(s) four times daily.
None Documented
None Documented
Terminal elimination half-life is approximately 10-15 hours in adults; prolonged in hepatic impairment.
Terminal elimination half-life of amfenac is approximately 0.7 hours in plasma, but due to prolonged residence in ocular tissues, the clinical effect lasts up to 24 hours with once-daily dosing.
Renal excretion (approximately 70%) as unchanged drug and metabolites; biliary/fecal excretion accounts for the remainder.
Nepafenac is extensively metabolized, and its active metabolite amfenac is primarily excreted renally (approximately 80% as metabolites, including amfenac glucuronide, and 20% as unchanged drug in urine). Biliary/fecal excretion accounts for less than 10%.
Category C
Category C
Ophthalmic NSAID
Ophthalmic NSAID